5种单克隆抗体预防视神经脊髓炎谱系疾病复发的有效性网状Meta分析及安全性评价

关茗元; 王婷; 段冉冉; 李莹

doi:10.6039/j.issn.1001-0408.2023.05.18

您当前的位置：

首页 >

文章列表页 >

5种单克隆抗体预防视神经脊髓炎谱系疾病复发的有效性网状Meta分析及安全性评价

循证药学 | 更新时间：2023-06-12

- 5种单克隆抗体预防视神经脊髓炎谱系疾病复发的有效性网状Meta分析及安全性评价
- Efficacy and safety of five monoclonal antibodies in preventing relapse of neuromyelitis optica spectrum disorders： network meta-analysis
- 中国药房 2023年34卷第5期页码：607-612
- 作者机构：
  
  1.郑州大学第一附属医院药学部，郑州　450052
  2.郑州大学第一附属医院神经内科，郑州　450052
- 作者简介：
  
  药师，硕士研究生。研究方向：临床药学。E-mail：goldenmoonsp@163.com
  副主任药师，硕士生导师，博士。研究方向：临床药学。E-mail：liyingpds@126.com
- 基金信息：
  
  河南省科技发展计划项目(182102310169)
- DOI：10.6039/j.issn.1001-0408.2023.05.18
  中图分类号： R744.5;R969.3
- 纸质出版日期：2023-03-15，
  
  收稿日期：2022-08-01，
  
  修回日期：2023-01-10，
扫描看全文
关茗元,王婷,段冉冉等.5种单克隆抗体预防视神经脊髓炎谱系疾病复发的有效性网状Meta分析及安全性评价 ^Δ[J].中国药房,2023,34(05):607-612.

GUAN Mingyuan,WANG Ting,DUAN Ranran,et al.Efficacy and safety of five monoclonal antibodies in preventing relapse of neuromyelitis optica spectrum disorders： network meta-analysis[J].ZHONGGUO YAOFANG,2023,34(05):607-612.
关茗元,王婷,段冉冉等.5种单克隆抗体预防视神经脊髓炎谱系疾病复发的有效性网状Meta分析及安全性评价 ^Δ[J].中国药房,2023,34(05):607-612. DOI： 10.6039/j.issn.1001-0408.2023.05.18.

GUAN Mingyuan,WANG Ting,DUAN Ranran,et al.Efficacy and safety of five monoclonal antibodies in preventing relapse of neuromyelitis optica spectrum disorders： network meta-analysis[J].ZHONGGUO YAOFANG,2023,34(05):607-612. DOI： 10.6039/j.issn.1001-0408.2023.05.18.

摘要

目的

间接比较利妥昔单抗、托珠单抗、依库珠单抗、伊奈利珠单抗及萨特利珠单抗预防视神经脊髓炎谱系疾病复发的有效性并评价其安全性，为临床用药提供参考。

方法

计算机检索Embase、Medline、PubMed、中国知网和临床试验注册数据库ClinicalTrials.gov、UMIN Clinical Trials Registry、中国临床试验注册中心，收集5种单克隆抗体（试验组）对比安慰剂或其他治疗方案（对照组）的随机对照试验，检索时限为各数据库建库起至2022年4月。由2位研究者独立筛选文献、提取资料，并采用Cochrane风险偏倚评估工具对纳入文献的质量进行评价；采用OpenBUGS软件进行网状Meta分析。安全性方面，对报告中试验组与对照组不良事件发生情况的差异进行

检验。

结果

共纳入7项随机对照试验，涉及793例患者。各指标的累积排序概率曲线下面积（SUCRA）排序结果显示，在降低复发风险方面，依库珠单抗＞利妥昔单抗＞伊奈利珠单抗＞萨特利珠单抗；在降低年复发率方面，依库珠单抗＞萨特利珠单抗；在改善残疾进展方面，依库珠单抗＞萨特利珠单抗＞伊奈利珠单抗＞利妥昔单抗＞托珠单抗。安全性评方面的

检验结果显示，各项研究总体不良事件及严重不良事件的发生风险与对照组比较，差异均无统计学意义（

＞0.05），但利妥昔单抗组患者输液反应、恶心呕吐及依库珠单抗组患者上呼吸道感染发生率显著高于安慰剂组（

＜0.05）。

结论

依库珠单抗在上述3种结局指标上的效果均为最优；在改善残疾进展方面，依库珠单抗、萨特利珠单抗及伊奈利珠单抗效果优于其他2种药物；安全性方面，部分不同分级及单项不良事件存在显著性差异，但未发现其与已有的文献及药品说明书的报告结果不一致。

Abstract

OBJECTIVE

To indirectly compare and evaluate the efficacy and safety of rituximab， tocilizumab， eculizumab， inebilizumab and satralizumab in preventing the relapse of neuromyelitis optica spectrum disorders， so as to provide reference for clinical drug use.

METHODS

Retrieved from Embase， Medline， PubMed， CNKI， ClinicalTrials.gov， UMIN Clinical Trials Registry and Chinese Clinical Trial Registry， randomized controlled trials （RCTs） about five monoclonal antibodies （trial group） versus placebo or other therapeutic scheme （control group） were collected during the inception to Apr. 2022. Two reviewers independently screened literature， extracted data， and assessed the quality of included literature with Cochrane risk bias assessment tool. OpenBUGS software was used for network meta-analysis. In terms of safety， Chi-square test was performed for adverse events （AEs） in trial group and control group.

RESULTS

A total of 7 RCTs were included， involving 793 patients. The results of surface under the cumulative ranking curve （SUCRA） showed the order of capabilities decreasing relapse risk was： eculizumab＞rituximab＞inebilizumab＞satralizumab； the order of capabilities reducing the annual recurrence rate was： eculizumab＞satralizumab； the order of capabilities improving the progress of disability was： eculizumab＞satralizumab＞inebilizumab＞rituximab＞tocilizumab. In terms of safety， the results of

test showed that there were no statistically significant differences in the risk of total AEs and serious AEs in each study between trial groups and control groups （

＞0.05）； the incidence of infusion reaction， nausea and vomiting in rituximab group， and that of upper respiratory tract infection in eculizumab group were significantly higher than placebo group （

＜0.05）.

CONCLUSIONS

The effect of eculizumab is more optimal in three outcomes； in terms of improving the progress of disability， eculizumab， satralizumab and inebilizumab are more effective than the other two drugs； in terms of safety， there are significant differences in some AEs with different grades and individual AEs， but it is not found that they are inconsistent with the reported results of the existing literature and drug instructions.

关键词

利妥昔单抗托珠单抗依库珠单抗伊奈利珠单抗萨特利珠单抗视神经脊髓炎谱系疾病预防复发网状Meta分析

Keywords

tocilizumabeculizumabinebilizumabsatralizumabneuromyelitis optica spectrum disorderpreventing relapsenetwork meta-analysis

references

WINGERCHUK D M，BANWELL B，BENNETT J L， et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology，2015，85（2）：177-189.

PAPP V，MAGYARI M，AKTAS O，et al. Worldwide incidence and prevalence of neuromyelitis optica：a syste- matic review[J]. Neurology，2021，96（2）：59-77.

SELLNER J，BOGGILD M，CLANET M，et al. EFNS guidelines on diagnosis and management of neuromyelitis optica[J]. Eur J Neurol，2010，17（8）：1019-1032.

中国免疫学会神经免疫分会. 中国视神经脊髓炎谱系疾病诊断与治疗指南：2021版[J]. 中国神经免疫学和神经病学杂志，2021，28（6）：423-436.

LUNN D，SPIEGELHALTER D，THOMAS A，et al. The BUGS project：evolution，critique and future directions[J]. Stat Med，2009，28（25）：3049-3067.

JANSEN J P，TRIKALINOS T，CAPPELLERI J C，et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making：an ISPOR-AMCP-NPC good practice task force report[J]. Value Health，2014，17（2）：157-173.

WINGERCHUK D M，LENNON V A，LUCCHINETTI C F，et al. The spectrum of neuromyelitis optica[J]. Lancet Neurol，2007，6（9）：805-815.

WINGERCHUK D M，LENNON V A，PITTOCK S J，et al. Revised diagnostic criteria for neuromyelitis optica[J]. Neurology，2006，66（10）：1485-1489.

LU G，BEADNALL H N，BARTON J，et al. The evolution of “No Evidence of Disease Activity” in multiple sclerosis[J]. Mult Scler Relat Disord，2018，20：231-238.

GREEN S，HIGGINS J P. Preparing a cochrane review[M]//Cochrane Handbook for Systematic Reviews of Interventions. Chichester，UK：John Wiley & Sons，Ltd.，2008：11-30.

MACHIN D，CHEUNG Y B，PARMAR M K B，et al. Survival analysis ：a practical approach[M]. 2nd ed. Chichester，Hoboken，NJ：Wiley，2006：1-25.

DIAS S，SUTTON A J，ADES A E，et al. Evidence synthesis for decision making 2：a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials[J]. Med Decis Making，2013，33（5）：607-617.

WOODS B S，HAWKINS N，SCOTT D A. Network meta-analysis on the log-hazard scale，combining count and hazard ratio statistics accounting for multi-arm trials：a tutorial[J]. BMC Med Res Methodol，2010，10：54.

SALANTI G，ADES A E，IOANNIDIS J P A. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis：an overview and tutorial[J]. J Clin Epidemiol，2011，64（2）：163-171.

NIKOO Z，BADIHIAN S，SHAYGANNEJAD V，et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder：a randomized clinical trial[J]. J Neurol，2017，264（9）：2003-2009.

TAHARA M，OEDA T，OKADA K，et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders （RIN-1 study）：a multicentre，randomised，double-blind，placebo-controlled trial[J]. Lancet Neurol，2020，19（4）：298-306.

ZHANG C，ZHANG M N，QIU W，et al. Safety and efficacy of tocilizumab versus azathioprine in highly relap- sing neuromyelitis optica spectrum disorder （TANGO）：an open-label，multicentre，randomised，phase 2 trial[J]. Lancet Neurol，2020，19（5）：391-401.

YAMAMURA T，KLEITER I，FUJIHARA K，et al. Trial of satralizumab in neuromyelitis optica spectrum disorder[J]. N Engl J Med，2019，381（22）：2114-2124.

TRABOULSEE A，GREENBERG B M，BENNETT J L，et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder：a randomised，double-blind，multicentre，placebo-controlled phase 3 trial[J]. Lancet Neurol，2020，19（5）：402-412.

PITTOCK S J，BERTHELE A，FUJIHARA K，et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder[J]. N Engl J Med，2019，381（7）：614-625.

CREE B A C，BENNETT J L，KIM H J，et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder （N-MOmentum）：a double-blind，randomised placebo-controlled phase 2/3 trial[J]. Lancet，2019，394（10206）：1352-1363.

MARIGNIER R，BENNETT J L，KIM H J，et al. Disabi- lity outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder[J]. Neurol Neuroimmunol Neuroinflamm，2021，8（3）：e978.

DIAS S，WELTON N J，SUTTON A J，et al. Evidence synthesis for decision making 4：inconsistency in networks of evidence based on randomized controlled trials[J]. Med Decis Making，2013，33（5）：641-656.

VAN VALKENHOEF G，DIAS S，ADES A E，et al. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis[J]. Res Synth Methods，2016，7（1）：80-93.

WINGERCHUK D M，ZHANG I，KIELHORN A，et al. Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder[J]. Neurol Ther，2022，11（1）：123-135.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

三联方案防治中高度致吐风险化疗药物致急性恶心呕吐疗效的网状Meta分析

转移性激素敏感性前列腺癌药物治疗方案的网状Meta分析

不同药物方案治疗儿童川崎病疗效和安全性的网状Meta分析

SGLT-2抑制剂致2型糖尿病患者低血糖的网状Meta分析

4种蛇毒血凝酶联合质子泵抑制剂用于非静脉曲张上消化道出血疗效和安全性的网状Meta分析